文献速递冠心病心力衰竭与心肌病

克隆性造血对急性心肌梗死合并心源性休克患者预后的影响

Impact of Clonal Hematopoiesis in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究基于CULPRIT-SHOCK试验纳入的446例急性心肌梗死合并心源性休克患者,采用靶向下一代测序检测克隆性造血(CHIP)。结果显示29%的患者携带≥2%变异等位基因频率的CHIP变异,最常见于DNMT3A和TET2基因,CHIP携带者30天不良结局更差,且复合终点关联独立于年龄及肾功能、心衰严重程度和炎症生物标志物。

要点

  • AMI合并心源性休克患者中CHIP常见,检出率29%,以DNMT3A和TET2突变为主。
  • CHIP携带者30天死亡或严重肾衰复合终点风险升高,校正后OR 1.83(95%CI 1.05-3.21,P=0.03)。
  • CHIP或可用于心源性休克患者的风险分层,并提示新的治疗靶点。

核心结论

  • 在急性心肌梗死合并心源性休克患者中,CHIP常见且与临床结局受损相关。
  • CHIP与30天死亡或严重肾衰复合终点的关联独立于年龄及反映肾功能、心衰严重程度和炎症的生物标志物。
  • CHIP与30天全因死亡的关联未达统计学显著性(OR 1.67;95%CI 0.96-2.90;P=0.069)。

研究设计与样本

  • 基于CULPRIT-SHOCK试验(NCT01927549)的血液样本分析,共纳入446例患者。
  • 血样于随机化时获取,采用靶向最常见突变基因的下一代测序方法评估CHIP。
  • 主要结局为30天全因死亡与肾脏替代治疗的复合终点。

主要发现

  • 29%(n=129)的患者检出变异等位基因频率≥2%的CHIP变异。
  • DNMT3A和TET2基因分别携带全部突变的47%和36%。
  • CHIP携带者较非携带者年龄更大,肾功能下降,N末端B型利钠肽前体和炎症生物标志物水平升高。
  • CHIP携带者30天死亡或严重肾衰复合终点更差(OR 1.83;95%CI 1.05-3.21;P=0.03)。

关键数值与推荐

  • CHIP定义:变异等位基因频率≥2%。
  • 主要结局:30天全因死亡与肾脏替代治疗的复合终点。
  • 复合终点校正OR 1.83(95%CI 1.05-3.21;P=0.03);全因死亡OR 1.67(95%CI 0.96-2.90;P=0.069)。

临床怎么用

  • 对AMI合并心源性休克患者,可考虑评估CHIP以辅助风险分层。
  • CHIP携带者炎症及心衰生物标志物更高、肾功能更差,提示需更密切监测。
  • CHIP相关通路可能成为新的治疗靶点,但尚需前瞻性验证。

局限性

  • 研究为基于CULPRIT-SHOCK试验样本的事后分析,样本量446例。
  • CHIP与全因死亡的关联未达统计学显著性。
  • 摘要未报告CHIP检测基因Panel的具体范围及随访时间等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is common in elderly individuals and is associated with an increased risk of both hematologic malignancies and cardiovascular disease. The impact of CHIP on the outcomes for patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI) remains undetermined. OBJECTIVES: The purpose of this study was to determine the prognostic impact of CHIP in CS after AMI. METHODS: Blood samples were obtained at randomization from 446 patients included in the CULPRIT-SHOCK (Culprit Lesion Only vs Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock; NCT01927549) trial. CHIP was assessed using a next-generation sequencing approach targeting the most commonly mutated genes; the primary outcome at 30 days comprised all-cause mortality and renal replacement therapy. RESULTS: CHIP variants at ≥2% variant allele frequency were detected in 29% (n = 129), most commonly in the DNMT3A or TET2 genes, which harbored 47% and 36% of all mutations, respectively. Compared to non-CHIP patients, CHIP carriers were older and had decreased renal function and increased levels of N-terminal pro-B-type natriuretic peptide and inflammatory biomarkers. CHIP carriers had worse short-term outcomes measured either as mortality or as the combined clinical endpoint of mortality or severe renal failure within 30 days. Association of CHIP with the combined endpoint was independent of age and biomarkers reflecting kidney function, heart failure severity, and inflammation (OR: 1.83; 95% CI: 1.05-3.21; P = 0.03) but not significant regarding all-cause mortality (OR: 1.67; 95% CI: 0.96-2.90; P = 0.069). CONCLUSIONS: CHIP is frequent among AMI and CS patients and is associated with impaired clinical outcome. CHIP assessment may facilitate risk stratification in patients with CS and imply novel treatment targets. (Culprit Lesion Only vs Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock [CULPRIT-SHOCK]; NCT01927549).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Böhme, Desch, Rosolowski, et al. Impact of Clonal Hematopoiesis in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction. J Am Coll Cardiol. 2022. PMID: 36229091. doi:10.1016/j.jacc.2022.08.740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。